Clinical Trials Become Complex One Good Decision at a Time
Nobody has ever walked into a protocol review meeting and said,
“Let’s make this study harder for patients.”
Or,
“Let’s make life a little more difficult for sites.”
Or,
“Let’s add unnecessary complexity.”
Those conversations don’t happen.
In my experience, the opposite is true.
Every person in the room is trying to make the study better.
Which raises an interesting question.
If everyone is trying to improve clinical trials, why do so many become more complicated than anyone intended?
For a long time, I assumed complexity was simply the price of ambitious science. Bigger questions required bigger studies. More uncertainty required more data. If a protocol was difficult to execute, I assumed that was because the science demanded it.
After sitting through hundreds of protocol discussions, I don’t think that’s what usually happens.
I think complexity arrives much more quietly than that.
It starts with one reasonable conversation
Most protocols don’t become difficult because of one dramatic decision.
They become difficult because of a series of thoughtful ones.
Someone asks whether another biomarker might help answer an important scientific question. It’s a good idea. If samples are already being collected, why not learn a little more while the opportunity is there?
Later, the conversation shifts. Would another imaging assessment strengthen the safety package? It probably would. A statistician wonders whether one additional endpoint would provide greater confidence in the findings. An investigator points out that one eligibility criterion may not be strict enough. A patient representative raises a valid concern about monitoring.
None of those conversations feels controversial.
In fact, they’re exactly the conversations you would hope a thoughtful protocol team is having.
Everyone is bringing expertise. Everyone is improving something.
The interesting part only becomes visible later.
No one experiences those decisions one at a time.
Patients experience them together.
Sites execute them together.
And that’s where complexity begins.
Looking at the same protocol through different eyes
One of the things I’ve come to appreciate is that protocol development isn’t simply about writing a scientific document.
It’s about bringing together people who all care deeply about the same study, but naturally see it through different lenses.
Medical is thinking about the questions that still need answering.
Safety is thinking about risk.
Statistics is thinking about confidence.
Clinical pharmacology is thinking about what else can be learned.
Investigators are imagining what this study will actually look like in a busy clinic.
Clinical Operations is already thinking about whether sites can realistically deliver everything that’s being proposed.
Every perspective makes the protocol stronger.
The challenge is that they don’t add their ideas to an empty document.
They add them to one that’s already growing.
One more procedure rarely changes a study.
Twenty more eventually do.
What every addition really costs
Over the years, I’ve found myself asking a different question.
Not just,
“Should we add this?”
But,
“What will this cost?”
I don’t mean financially.
I mean operationally.
Humanly.
Every additional assessment takes time.
Every extra visit asks something more of a patient.
Every new procedure creates work for a coordinator who’s already juggling dozens of competing priorities.
Those costs don’t appear beside the proposed change during protocol review.
They’re paid months later by people who weren’t sitting around the conference table when the decision was made.
That’s why they’re so easy to overlook.
The protocol eventually leaves the conference room
One of the easiest things to forget is that protocols don’t stay on paper.
Eventually, every page becomes someone’s experience.
Someone’s calendar.
Someone’s commute.
Someone’s childcare arrangement.
Someone’s infusion.
Someone’s missed day of work.
Someone’s Tuesday.
When I think about the best protocols I’ve worked on, I don’t remember them because they collected the most information.
I remember them because they remained remarkably disciplined about the information that mattered most.
That doesn’t mean asking fewer scientific questions.
It means being intentional about which questions truly belong in this study, at this moment, for these patients.
After more than twenty years in clinical research, I’ve come to believe that overly complex trials rarely emerge because someone made one bad decision.
More often, they emerge because dozens of good decisions were never experienced together.
Perhaps that’s one of the hardest responsibilities in protocol design.
Not deciding what else we could learn.
Having the discipline to decide what the study truly needs.